Welcome to our dedicated page for Argent BioPharma news (Ticker: RGTLF), a resource for investors and traders seeking the latest updates and insights on Argent BioPharma stock.
Argent BioPharma Ltd. (ASX: RGT, OTCQB: RGTLF) generates news that reflects its role as a clinical-stage biopharmaceutical company focused on neuroimmunology, neuro-immune modulation, and advanced nano-medicine. News coverage often centers on its pipeline of proprietary therapeutics for central nervous system disorders, immune-related conditions, inflammatory diseases, and advanced wound care.
Recent announcements have highlighted clinical trial progress, such as Phase IIb results for CimetrA®, a novel anti-inflammatory treatment in COVID-19 patients. These updates include details on safety profiles, clinical improvement versus placebo, and modulation of inflammatory markers like IL-6, IL-1β, and TNF-α. Other news has focused on CannEpil®, a high-CBD, low-THC oral mucosal solution designed to reduce seizure frequency and severity while minimizing psychoactive effects, and its role in severe epilepsy treatment efforts.
Argent BioPharma’s news flow also includes strategic and operational developments. Examples include capital-raising activities to fund its drug development pipeline, restructuring of EU GMP-certified manufacturing facilities in Slovenia and Malta through transfers to third-party operators, and commentary on cost savings intended to support research and clinical programs. Geographic expansion is another theme, with announcements about regulatory approval and initial purchase orders for CannEpil® and CogniCann® in Germany, described by the company as the largest healthcare market in Europe.
In addition, updates on the collaboration with SINTEF in Norway provide insight into Argent BioPharma’s work on nano-encapsulated antimicrobial therapies for chronic wound management and potential oncologic wound care. Visitors to this news page can review company-issued releases covering clinical data, partnerships, operational changes, and financing events that shape Argent BioPharma’s development trajectory.
Argent BioPharma (ASX: RGT, OTCQB: RGTLF) has announced its entry into the German pharmaceutical market, securing initial purchase orders for CannEpil® and CogniCann® following regulatory approval. Germany, being Europe's largest healthcare market, represents a significant commercial milestone for the company's European expansion strategy.
The clinical-stage biopharmaceutical company has also completed the transfer of its EU GMP-certified manufacturing facilities in Slovenia and Malta to third-party operators. This operational restructuring is expected to generate annual cost savings of over $1 million while maintaining GMP compliance. The freed capital will be directed towards accelerating R&D initiatives and clinical trials across core therapeutic programs.
Argent BioPharma (ASX: RGT, OTCQB: RGTLF) has announced positive Phase IIb clinical trial results for its novel anti-inflammatory treatment, CimetrA®. The trial demonstrated significant benefits in COVID-19 patients, including:
- No drug-related adverse events
- Faster clinical improvement compared to placebo (WHO Ordinal Scale)
- Reduced inflammation with modulation of key markers (IL-6, IL-1β, TNF-α)
- Improved quality of life trends
The company is also developing CannEpil®, an oral mucosal solution with high-CBD and low-THC formulation, designed for severe epilepsy treatment. The drug is currently making progress in the UK market.
Argent BioPharma (ASX: RGT, OTCQB: RGTLF) reports progress in its collaboration with SINTEF on enhancing antimicrobial therapies for chronic wounds and oncologic wound care. The company has advanced its proprietary antimicrobial compounds using nano-encapsulation technology to improve drug efficacy and targeted delivery.
Key achievements include establishing standardized in vitro assays, identifying Synthetic Wound Fluid (SWF) as the optimal testing medium, and selecting promising APIs with pH-dependent antimicrobial activity. The research targets diabetic foot ulcers, pressure sores, post-surgical infections, and non-melanoma skin cancer excisions.
The next phase will focus on refining API combinations for nano-encapsulation and conducting Minimum Inhibitory Concentration studies. The initiative aims to address biofilm formation, antibiotic resistance, and chronic infections in a global advanced wound care market projected to exceed $15 billion by 2030.
Argent BioPharma (ASX:RGT) (OTCQB:RGTLF) has successfully completed a US$4.5 million capital raise through a placement of 5,625,000 Units at US$0.80 each. Each Unit includes two ordinary shares and one warrant exercisable at US$0.55 with a three-year expiry.
The placement will be executed in two tranches: Tranche 1 with 5,000,000 shares and 2,500,000 warrants issued immediately, and Tranche 2 with 6,250,000 shares and 3,125,000 warrants subject to shareholder approval. The shares are priced at US$0.40, representing a 370% premium to the 15-day VWAP.
The funds will support Argent's drug development pipeline, particularly CannEpil® clinical studies. The company is conducting a strategic review following LSE delisting and preparing for US National Listing. Sputnik Enterprises , acting as corporate advisor, will receive a 5% cash fee and 1,125,000 warrants.
Argent BioPharma (ASX: RGT) (OTCQB: RGTLF) has successfully completed a US$4.5 million capital raise through a placement of 5,625,000 Units at US$0.80 each. Each Unit includes two ordinary shares and one warrant exercisable at US$0.55 with a three-year expiry.
The placement will be executed in two tranches: Tranche 1 with 5,000,000 shares and 2,500,000 warrants issued immediately, and Tranche 2 with 6,250,000 shares and 3,125,000 warrants pending shareholder approval. The placement shares are priced at US$0.40, representing a 370% premium to the 15-day VWAP.
The funds will support Argent's drug development pipeline, particularly CannEpil® clinical studies. The company is conducting a strategic review following LSE delisting and preparing for US National Listing. Sputnik Enterprises , acting as corporate advisor, will receive a 5% cash fee and 1,125,000 warrants.